Infectious Disease

Tuberculosis

216

Pipeline Programs↗

51

Active Trials↗

47

Companies Involved↗

Tuberculosis is a highly competitive landscape with 216 programs across 47 companies. The most active players are Glaxo Dba Glaxosmithkline, Agouron Pharmaceuticals, MAXVAX Biotechnology Limited Liability Company. 32 therapies are approved with 50 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

82/100

Pipeline Velocity

45/100

Mech. Concentration

13/100

Completion Rate

84/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Glaxo Dba Glaxosmithkline

1 program

Agouron Pharmaceuticals

1 program

MAXVAX Biotechnology Limited Liability Company

1 program

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

1 program

Lundbeck

1 program

Barinthus Biotherapeutics

1 program

Pipeline

Programs by Phase

Preclinical33

Pyrazinamide

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Silymarin

Bukwang Pharmaceutical

Delamanid

Otsuka

Cabotegravir

GSK

Doravirine

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 150

Etoricoxib

Novartis

Celecoxib

Philadelphia Eye Associates

Allopurinol

Alnylam Pharmaceuticals

Azacitidine

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

AERAS-402

Aeras

Phase 251

Ibuprofen

Kenvue Brands

Rifabutin

Pfizer

Adalimumab

Celltrion

Doxycycline

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Methylprednisolone

Pfizer

Phase 350

Cholecalciferol

Hyundai Pharmaceutical Co., LTD.

BCG Vaccine

Gynecologic Oncology Group

Bacillus Calmette-Guerin

AstraZeneca

Selenium

SWOG Cancer Research Network

Moxifloxacin

Bayer

Approved32

Ethambutol

VA Greater Los Angeles Healthcare System

Isoniazid

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Rifapentine

Sanofi

Midazolam

Conrado Roberto Hoffmann Filho

Ergocalciferol

Alnylam Pharmaceuticals

Analysis

Modality Breakdown

90%

Small molecule

218 of 242 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 242 classified programs, each share of the total. Modality classified for 100% of 298 pipeline programs.

Analysis

Trial Status

284

clinical trials

Completed174 · 61%

Unknown status27 · 10%

Recruiting20 · 7%

Terminated18 · 6%

Active, not recruiting14 · 5%

Not yet recruiting14 · 5%

Other17 · 6%

Clinical Trials

Trial Activity

284 trials

Adjunctive Acetylsalicylic Acid and Ibuprofen for Tuberculosis

Recruiting·FFundació Institut Germans Trias i Pujol·Phase 2·NCT04575519·354 enrolled

Short Course Regimen in Low Risk Active Tuberculosis- a Multicenter, Randomized, Active-controlled, Trial

Recruiting·KKaohsiung Veterans General Hospital.·Phase 3·NCT06727864·270 enrolled

Window Prophylaxis for Pediatric Tuberculosis Prevention Trial

Recruiting·PPontificia Universidad Catolica de Chile·N/A·NCT07086820·647 enrolled

Study of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children With Rifampicin-Resistant Tuberculosis

Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT05586230·72 enrolled

Clinical Trial to Evaluate the Efficacy and Safety of EEC for the Diagnosis of Mycobacterium Tuberculosis Infection in People Aged 3 Years and Above

Recruiting·CChengdu CoenBiotech Co., Ltd·Phase 3·NCT07152639·1,784 enrolled

Characterization of Tuberculosis Associated Lung Fibrosis and Respiratory Impairment, and Prevention Using Doxycycline

Recruiting·MMakerere University·Phase 2·NCT06477185·200 enrolled

Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis

Recruiting·AANRS, Emerging Infectious Diseases·Phase 2·NCT05590455·130 enrolled

Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis

Recruiting·UUniversity of California, San Francisco·Phase 2/3·NCT06441006·400 enrolled

Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of RESP30TB in Tuberculosis

Recruiting·TThirty Respiratory Limited·Phase 2·NCT07073638·24 enrolled

Adjunctive Doxycycline for Central Nervous System Tuberculosis

Recruiting·NNational University Hospital, Singapore·Phase 2·NCT06446245·200 enrolled

Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine MTBVAC in Healthy Indian Adults and Adolescents (BBV169/2024)

Recruiting·BBharat Biotech International Limited·Phase 2·NCT06997367·164 enrolled

Population Pharmacokinetics of Anti-tuberculosis Drugs in Children With Tuberculosis

Recruiting·—·N/A·NCT03625739·800 enrolled

Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis (TEDITUB)

Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT05534750·60 enrolled

Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein for 65-year-olds and Above

Recruiting· Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. logo

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.·Phase 3·NCT05899179·780 enrolled

Novel Triple-dose Tuberculosis Retreatment Regimen

Recruiting·IInstitute of Tropical Medicine, Belgium·Phase 3·NCT04260477·370 enrolled

Page 1 of 19

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)